Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
October 26, 2021
Ryan Allway October 26th, 2021 Psychedelics Output will be used to advance clinical testing of MEAI as a treatment for Alcohol Use Disorder and Binge Drinking TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech... Read more
